Literature DB >> 15516873

Relation between in vitro and in vivo osteogenic potential of cultured human bone marrow stromal cells.

S C Mendes1, J M Tibbe, M Veenhof, S Both, F C Oner, C A van Blitterswijk, J D de Bruijn.   

Abstract

The use of cell therapies in bone reconstruction has been the subject of extensive research. It is known that human bone marrow stromal cell (HBMSC) cultures contain a population of progenitor cells capable of differentiation towards the osteogenic lineage. In the present study, the correlation between the in vitro osteogenic potential of HBMSC cultures and their capacity to form bone in vivo was investigated. HBMSC cultures were established from 14 different donors. Fourth passage cells were examined for the expression of alkaline phosphatase (ALP), procollagen I (PCI) and osteopontin (OP), through flow cytometry and the effect of the osteogenic differentiation factor dexamethasone (Dex) on this expression was evaluated. In addition, the capacity of the cultures to induce in vivo bone formation was analysed by culturing the cells on porous hydroxyapatite (HA) scaffolds followed by subcutaneous implantation of these constructs in nude mice. Results showed expression of PCI, OP and ALP in all cultures, irrespective of the presence of Dex in the culture medium. Dex failed to have a significant effect on the expression of PCI and OP but it induced a consistent increase in the relative amount of cells expressing ALP. Nevertheless, although in vitro testing clearly indicated osteogenic potential in all cultures, HBMSC from six of the 14 tested donors did not form bone in vivo. The results, therefore, demonstrate that neither the expression of PCI, OP and ALP nor the absolute increase in Dex-stimulated ALP expression can as yet be used as predictive markers for in vivo bone formation by HBMSC. However, preliminary data indicate that not the absolute, but the relative increase in the percentage of ALP expressing cells caused by Dex stimulation may be related to the ability of the HBMSC to form bone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516873     DOI: 10.1023/B:JMSM.0000046394.53153.21

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  36 in total

1.  Monoclonal antibodies reactive with human osteogenic cell surface antigens.

Authors:  S P Bruder; M C Horowitz; J D Mosca; S E Haynesworth
Journal:  Bone       Date:  1997-09       Impact factor: 4.398

2.  Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts.

Authors:  P H Krebsbach; S A Kuznetsov; K Satomura; R V Emmons; D W Rowe; P G Robey
Journal:  Transplantation       Date:  1997-04-27       Impact factor: 4.939

3.  Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow.

Authors:  I Martin; A Muraglia; G Campanile; R Cancedda; R Quarto
Journal:  Endocrinology       Date:  1997-10       Impact factor: 4.736

Review 4.  Future potentials for using osteogenic stem cells and biomaterials in orthopedics.

Authors:  R O Oreffo; J T Triffitt
Journal:  Bone       Date:  1999-08       Impact factor: 4.398

5.  Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacrylate-embedded adult human bone in combination with histomorphometry.

Authors:  P Derkx; A L Nigg; F T Bosman; D H Birkenhäger-Frenkel; A B Houtsmuller; H A Pols; J P van Leeuwen
Journal:  Bone       Date:  1998-04       Impact factor: 4.398

6.  Tissue engineering: a new field and its challenges.

Authors:  R Langer
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

7.  Isolation and characterization of human clonogenic osteoblast progenitors immunoselected from fetal bone marrow stroma using STRO-1 monoclonal antibody.

Authors:  B O Oyajobi; A Lomri; M Hott; P J Marie
Journal:  J Bone Miner Res       Date:  1999-03       Impact factor: 6.741

8.  Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age.

Authors:  S C Mendes; J M Tibbe; M Veenhof; K Bakker; S Both; P P Platenburg; F C Oner; J D de Bruijn; C A van Blitterswijk
Journal:  Tissue Eng       Date:  2002-12

9.  A rapid, quantitative assay for measuring alkaline phosphatase activity in osteoblastic cells in vitro.

Authors:  A Sabokbar; P J Millett; B Myer; N Rushton
Journal:  Bone Miner       Date:  1994-10

10.  Mesenchymal stem cells.

Authors:  A I Caplan
Journal:  J Orthop Res       Date:  1991-09       Impact factor: 3.494

View more
  22 in total

1.  In vitro biocompatibility and corrosion resistance of a new implant titanium base alloy.

Authors:  E Vasilescu; P Drob; D Raducanu; V D Cojocaru; I Cinca; D Iordachescu; R Ion; M Popa; C Vasilescu
Journal:  J Mater Sci Mater Med       Date:  2010-03-25       Impact factor: 3.896

2.  In vitro osteogenic differentiation and in vivo bone-forming capacity of human isogenic jaw periosteal cells and bone marrow stromal cells.

Authors:  Claude Jaquiéry; Stefan Schaeren; Jian Farhadi; Pierre Mainil-Varlet; Christoph Kunz; Hans-Florian Zeilhofer; Michael Heberer; Ivan Martin
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  Interactions of total bone marrow cells with increasing quantities of macroporous calcium phosphate ceramic granules.

Authors:  Damien Le Nihouannen; Laure Duval; Antoine Lecomte; Marion Julien; Jérôme Guicheux; Guy Daculsi; Pierre Layrolle
Journal:  J Mater Sci Mater Med       Date:  2007-06-07       Impact factor: 3.896

4.  Mineralization of osteoblasts with electrospun collagen/hydroxyapatite nanofibers.

Authors:  J Venugopal; Sharon Low; Aw Tar Choon; T S Sampath Kumar; S Ramakrishna
Journal:  J Mater Sci Mater Med       Date:  2007-10-24       Impact factor: 3.896

5.  Mineralised collagen--an artificial, extracellular bone matrix--improves osteogenic differentiation of bone marrow stromal cells.

Authors:  Anne Bernhardt; Anja Lode; Sabine Boxberger; Wolfgang Pompe; Michael Gelinsky
Journal:  J Mater Sci Mater Med       Date:  2007-06-28       Impact factor: 3.896

6.  In vivo bone formation by progeny of human embryonic stem cells.

Authors:  Sergei A Kuznetsov; Natasha Cherman; Pamela Gehron Robey
Journal:  Stem Cells Dev       Date:  2010-09-14       Impact factor: 3.272

7.  Osteogenic Differentiation of Mesenchymal Stem Cells by Mimicking the Cellular Niche of the Endochondral Template.

Authors:  Fiona E Freeman; Hazel Y Stevens; Peter Owens; Robert E Guldberg; Laoise M McNamara
Journal:  Tissue Eng Part A       Date:  2016-09-28       Impact factor: 3.845

8.  In vivo formation of bone and haematopoietic territories by transplanted human bone marrow stromal cells generated in medium with and without osteogenic supplements.

Authors:  Sergei A Kuznetsov; Mahesh H Mankani; Pamela Gehron Robey
Journal:  J Tissue Eng Regen Med       Date:  2011-11-03       Impact factor: 3.963

9.  Lentiviral Gene Therapy for Bone Repair Using Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells.

Authors:  Sofia Bougioukli; Biagio Saitta; Osamu Sugiyama; Amy H Tang; Joseph Elphingstone; Denis Evseenko; Jay R Lieberman
Journal:  Hum Gene Ther       Date:  2019-04-22       Impact factor: 5.695

10.  Glucocorticoid receptor antagonist and siRNA prevent senescence of human bone marrow mesenchymal stromal cells in vitro.

Authors:  Na Wei; Yang Yu; Vijaya Joshi; Thomas Schmidt; Fang Qian; Aliasger K Salem; Clark Stanford; Liu Hong
Journal:  Cell Tissue Res       Date:  2013-08-21       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.